GSK Pharma forays into gynaecological cancer treatment in India

GlaxoSmithKline Pharmaceuticals Ltd. stock zoomed as much as 2% on Monday, August 25. This movement in shares came after the company announced its entry into the oncology segment in India with Jemperli and Zejula therapies that can be used for the treatment of gynaecological cancers.

At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE. The counter touched an intraday high and low of ₹2,869, and ₹2,797.50, respectively.

Jemperli is one and only approved programmed death receptor-1 (PD-1) immunotherapy. This will be used for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high advanced or recurrent endometrial cancer, in India.

This therapy blocks the PD-1 pathway. This is a mechanism that is used by cancer cells to evade immune detection, hence allowing immune cells to recognise and attack the tumor more effectively, informed the company in its filing with the bourses.

Additionally, Zejula is the only PARP (Poly(ADP-ribose) polymerase) inhibitor approved. This will be first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer in India, the company informed.

GSK also informed that it is planning to unveil a patient support programme for empowerment of patients to access these innovative therapies.

Related Posts

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

Chandauli – In yet another shocking case of alleged fraud in Uttar Pradesh’s health department, an FIR has been registered against a pharmacist for securing and continuing employment for nearly…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

Laughing all the Way to Health with Sir Ganga Ram Hospital

Laughing all the Way to Health with Sir Ganga Ram Hospital

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections